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ABSTRACT
Reported epidemiology references showed that vaginitis was caused either by bacteria (40-50%), Trichomonas (20-25%) or
Candida (15-20%). The objective of this study was to investigate the prevalence and strains distribution of vaginal candidiasis
in Taiwan. We evaluate the susceptibilities activity of fluconazole and amphotericin B against 101 Candida isolates from 97 patients
suffering from vaginal candidasis. Candida albicans was the most common species (67.3%), followed by C. glabrata (24.7%),
C. tropicalis (5.9%), C. parapsilosis (1%), and others (1%) among the identified strains. After evaluation by Etest, a total of 64
(63.4%) and 11 (10.9%) isolates were found to be susceptible, with dose dependent susceptibility, to fluconazole. All Candida isolates
were susceptible to amphotericin B with one isolate Saccharomyces cerevisiae being resistant to this drug. Ten out of 68 isolates
(14.7%) of C. albicans and 16 out of 25 isolates (64%) of C. glabrata showed fluconazole-resistant. C. glabrata commonly produced
higher minimum inhibitory concentrations than all the other species of Candida to triazole agents.
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INTRODUCTION
Vaginal candidiasis, caused by opportunist yeast,
Candida, is a common and increasing disease in women(1).
Approximately 75% of all women will have a vaginal
infection episode during their life span (2). Possible risk
factors causing an increase in Candida infections include
prior antibiotic therapy, pregnancy, diabetes mellitus (DM),
oral contraceptives containing estrogen and progestin, and
immunosuppressed patients (transplanted patients, cancer
patients treated with chemotherapy, and HIV patients)(2,3).
Candida albicans is the dominant species that caused a
prevalence of 70-90% of Candida vaginitis in various
reports(4). Only a minority of cases (< 10%) are caused by
non-albicans Candida species, usually C. glabrata and C.
tropicalis(4). However, a significant increase in non- C.
albicans species in some cases has been reported to be
associated with recurrent vaginal candidiasis (RVC) (5).
These epidemiological phenomena are hypothetical due to
incomplete eradications that either have increased
virulence, or are drug resistant(6). These changes suggest
that further investigation of clinical Candida colonization
and of its drug-resistant activity could bring discoveries that
might lead to the complete eradication of these infections,
or to the development of more effective antibiotic
protocols.
Traditionally, oral amphotericin B has long been con* Author for correspondence. Tel: +886-5-5370988 ext. 2162;
Fax: +886-5-5371449; E-mail: maxine@tit.edu.tw

sidered the “gold” standard for the treatment of vaginal
candidiasis; however, toxicities, poor taste acceptance, and
the need for multiple daily dosing limited its usefulness(7).
Today, a triazole antifungal agent, fluconazole, has been
used for inhibiting fungal cytochrome P-450 sterol C-14
alpha-demethylation of cell membrane ergosterol synthesis
pathways; it may be considered a reasonable alternative
because it is significantly less toxic than amphotericin B
and can be administered orally(8). Unfortunately, the invitro antifungal susceptibility compariation of fluconazole
and amphotericin B has not yet been identified clearly. The
objective of this study was to evaluate the in-vitro pharmacological activity of fluconazole and amphotericin B
against the clinical isolates of Candida according Etest, a
highly studied and popular methodology for clinical conventional minimum inhibitory concentration (MIC) determination.

MATERIALS AND METHODS
I. Strain Collection
Vaginal swabs were collected from 182 patients who
visited the Kuo General Hospital, a regional teaching
hospital of Tainan, Taiwan. Vaginal secretions were
cultured for 24 hr at 35˚C on Sabouraud’s dextrose agar
(Difco-BBL, USA), and each distinct colony was identified
by germ tube test (9) and with commercial biochemical
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panels API 20C (Biomerieux-Vitek, France). Growth at
45˚C on Sabouraud’s dextrose agar was used to distinguish
between C. albicans and C. dubliniensis. Then the Candida
species were identified on CHROMagar-Candida (DifcoBBL, USA), which is a chromgenic medium, allowing the
initial identification of C. albicans, C. tropicalis, and C.
krusei based on the colors and shapes of the colonies.
Candida selected for testing include 5 American Type
Culture Collection (ATCC) standard strains, C. albicans
ATCC10231, C. krusei ATCC6258, C. parasilosis
ATCC22019, C. tropicalis ATCC13803, and C. glabrata
ATCC90030.
II. Susceptibility Testing
Etest (AB BIODISK, Sweden) was applied for antifungal susceptibility test of Candida. Etest is an agar based
quantitative susceptibility technique, which combines the
concepts of both dilution and diffusion tests; comprised of a
predefined gradient of antifungal agent for determining the
minimum inhibitory concentration (MIC) in µ g/mL of
individual drugs. Each Candida isolate colony from a 24 hr
SDA plate was picked and homogenized well in 0.85%
saline to achieve 0.5 McFarland turbidity (0.5~2.5 × 103
CFU/mL). This suspension was spread with a sterile swab
on a PRMI 1640 plate (Sigma, USA) evenly onto the entire
surface, in three directions, allowing excessive moisture to
be absorbed for about 10-15 min, before applying the Etest
plastic strips on the agar. The strips were in complete
contact with the agar surface. Agar plates were incubated
in a moist incubator at 35˚C until growth is seen (24-72 hr),
before taking readings of the MIC values at the point of
intersection between the clear zone edge and the Etest strip.
For the fluconazole, the isolates were reported to be susceptible (S, MIC  8 µg/mL), susceptible-dose dependent (SDD, MIC16~32 µg/mL), or resistant (R, MIC ≥ 64 µg/mL)
according to the National Committee for Clinical
Laboratory Standards (NCCLS, 1997) (10) interpretive
breakpoint guidelines. A MIC  1 µg/mL was considered
susceptible to amphotericin B.

RESULTS
I. Species Distribution and Diversity
Of the original 182 clinical diagnostic candidiasis
patients enrolled in this study, 85 (47%) were either culturenegative or were cases of bacterial or Trichomonas
vaginosis . A total of 102 clinical yeast isolates were found
in 97 Candida culture-positive women with a recovery rate
of 53%. Of those, 49.5% (45/97) patients had a history of
recurrent vaginal candidiasis (RVC). An analysis by the
test of association of each pair of the following variables:
patient’s status (sporadic vaginal candidiasis or RVC),
clinical diagnostic (post-menopausal syndrome, oral antibiotics treatment, Diabetes mellitus, catamenia, pregnancy or

Table 1. Distribution of Candida species from visit patients
Candida species
No. (%) of isolates
Candida albicans
68 (67.3)
33 (32.6)
Non-albicans Candida
C. glabrata
25 (24.7)
C. tropicalis
6 (5.9)
C. parapsilosis
1 (1)
Candida sp.
1 (1)
Saccharomyces cerevisiae
1

other diseases), and fluconazole resistance (resistant, S-DD
or susceptible) showed no significant correlation (p > 0.05,
Pearson chi-square). All of the yeast isolates belonged to
the Candida species, except one, which was Saccharomyces
cerevisiae. The overall distribution of Candida spp. among
the 101 Candida isolates obtained is summarized in Table
1: C. albicans was the predominant species (67%),
followed by C. glabrata (25%), C. tropicalis (6%), C. parapsilosis (1%), and Candida sp. (1%). Five symptomatic
women yield more than one species of Candida. In three of
these patients, C. albicans and C. glabrata were isolated
from the vaginal swabs. The other two were infected by C.
albicans and C. tropicalis.
II. Fluconazole Susceptibility
The Etest analysis showed that overall, 26 (25.7%) of
Candida isolates were resistant to fluconazole, 11 (10.9%)
were determined as S-DD, and 64 (63.4%) were considered
fluconazole susceptible. Analysis of the 68 vaginal C.
albicans isolates revealed 10 (14.7%) resistant, and 3
(4.4%) S-DD isolates. The remaining 55 (80.9%) C.
albicans were susceptible. The other non-albicans 33
isolates showed 17 (51.5%) were fluconazole effective.
Alarmingly, 48.5% non-albicans Candida isolates were fluconazole ineffective, and all of them were C. glabrata
(Table 2).
III. Amphotericin B Susceptibility
The in vitro susceptibilities of Candida isolates with
amphotericin B revealed that all strains were susceptible
(MIC  1 µg/mL). It was completely effective for all C.
albicans and non-albicans Candida except for one S. cerevisiae isolate (Table 2).

DISCUSSION
The previous epidemiology reference showed that
vaginitis was caused either by bacteria (40-50%),
Trichomonas (20-25%) or Candida (15-20%)(11). In this
study, the incidence percentage of Candida vaginitis
(53.3%) showing sharp increases may be due to a growing
population of immunocompromised or immunosuppressed
diseases (12), and the sampling population was screened
from clinical candidal vaginitis women of signs and
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symptoms. Among the clinical isolates, C. albicans was
the most common species detected, followed by C.
glabrata. Similarities were observed compared to the
vaginal Candida distribution data from Malaysia(13).
Currently, Etest has been distributed as a time-saving
methodology for clinical antifungal susceptibility testing.
Fluconazole and amphotericin B Etest and NCCL microdilution methods have been compared extensively and shown
to produce a good agreement (14) . In this study, Etest
analysis results showed that 25.7% of Candida isolates were
resistant to fluconazole and more than one-half of these
strains belong to C. glabrata. Fluconazole susceptible percentage of C. albicans was 80.9% (at MIC  8 µg/mL),
close to the data of Argentina (87%) (15) and Belgium
(79%)(16), but with statistical significant difference from
those of Spain (100%)(17) and America (96%)(1) (Table 3).
The percentage of S-DD C. albicans was 10.9%; often
falling into the S-DD category. Identification of this yeast
often results in treatment with amphotericin B or other nonazole antifungal or higher dosage of azoles drugs. For
example, an antifungal susceptibility testing suggested that
a 400~800 mg daily dosage of fluconazole is likely to be
effective against fluconazole S-DD (MIC16~32 µg/mL) C.
albicans in the treatment of candidiasis(14).
A striking observation in this study is that 64% of the
C. glabrata isolates were fluconazole resistance. This percentage was far higher than the reported data of Spain
(4.3%)(17) and America (4.5%)(18). The present study is the

only drug susceptibility result of Candida isolates from
women with vaginal candidiasis in Taiwan, although one
previous drug resistance research indicated 47.3% of C.
albicans and 70% of C. glabrata collection from patients
with bloodstream infections in National Taiwan University
Hospital were fluconazole ineffective(12). C. glabrata is of
particular importance as an emerging fungal pathogen
because it appears to be innately resistant to moderate
levels of fluconazole(19). Some observations of certain
cases indicated that this drug resistance has been correlated
with either over-expression of membrane ergosterol
synthesis enzyme or the strain’s genetic modification(20).
Spinillo et al. have also shown that C. glabrata causes
approximately 20-30% of all recurrent candidiasis cases
and it’s possible that long-term or inappropriate maintenance treatment could encourage this selection of fluconazole resistance species(21).
S. cerevisiae has never been found to cause candidal
vaginitis(22). In this case, the only one S. cerevisiae isolate
showed resistance to both fluconazole (MIC = 48 µg/mL)
and amphotericin B (MIC ≥ 32 µg/mL). Its drug resistant
performance may be due to the lack of sterol D desaturase,
a drug target enzyme of cell membrane synthesis
pathway(23).
Knowledge of local antifungal susceptibility pattern, in
conjunction with knowledge of local prevalence or identification of more resistant species, can greatly aid in the
selection of effective antifungal agents for empirical use.

Table 2. Comparative susceptibilities of Candida vaginal isolates against fluconazole and amphotericin B
No. (%) of isolates
Candida species
No. of isolates
Fluconazole*
Sa
S-DDb
Rc
C. albicans
68
55 (80.9)
3 (4.4)
10 (14.7)
33
9 (27.3)
8 (24.2)
16 (48.5)
Non-albicans Candida
C. glabrata
25
1 (4)
8 (32)
16 (64)
C. tropicalis
6
6 (100)
0
0
C. parapsilosis
1
1 (100)
0
0
Candida sp.
1
1 (100)
0
0
S. cerevisiae
1
0
0
1 (100)
a
Susceptible (MIC  8 µg/mL).
b
Susceptible-dose dependent (MIC16~32 µg/mL).
c
Resistant (MIC ≥ 64 µg/mL).
d
Susceptible (MIC  1 µg/mL).
e
Resistant (MIC > 1 µg/mL).
*p < 0.001: Chi-squares, JMP (SAS Institute, USA).
**p = 0.08: Chi-squares, JMP (SAS Institute, USA).

Amphotericin B**
Sd
68 (100)
33 (100)
25 (100)
6 (100)
1 (100)
1 (100)
0

Table 3. Comparative susceptibilities of Candida albicans vaginal isolates against fluconazole of different countries
Country
No. (%) of isolates
This studya
Spainb,(17)
Americac,(18)
Argentinad,(15)
S*
55 (80.9)
108 (100)
373 (96)
79 (87)
S-DD**
3 (4.4)
0
2 (0.5)
0
R***
10 (14.7)
0
14 (3.5)
12 (13)
ab,ac
p < 0.005: Chi-squares, JMP (SAS Institute, USA).
ad,ae
p = 0.08: Chi-squares, JMP (SAS Institute, USA).
*Susceptible (MIC  8 µg/mL).
**Susceptible-dose dependent (MIC16~32 µg/mL).
***Resistant (MIC ≥ 64 µg/mL).

Re
0
0
0
0
0
0
1 (100)

Belgiume,(16)
68 (79)
0
18 (21)
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However, the role of antifungal susceptibility testing is
usually dependent on local availability and often cost
issues. On the basis of these results, we do recommend invitro susceptibility testing for patients with recurrent
vaginitis. In this setting, species identification and susceptibility testing may enhance antifungal selection and patient
response to treatment.
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